Hydroxyurea: a key player in cancer chemotherapy

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Hydroxyurea (HU) is an organic compound utilized as a chemotherapy agent.
• It functions by inhibiting ribonucleoside diphosphate reductase during the S-phase of the cell cycle.
• This inhibition limits de novo DNA synthesis, a critical process in cancer cell proliferation.

Purpose of the Study:

• To review the multifaceted effects of Hydroxyurea (HU) as a standalone and combination therapy in cancer treatment.
• To consolidate information on HU's mechanism of action, clinical applications, and associated toxicities.
• To provide a comprehensive overview for researchers and clinicians regarding HU's role in oncology.

Main Methods:

• Literature review of existing studies on Hydroxyurea (HU).
• Analysis of HU's mechanism of action, focusing on cell cycle inhibition.
• Compilation of data on HU's efficacy in various hematological disorders and solid tumors.
• Evaluation of clinical trial results for HU in combination therapies.
• Summary of reported side effects and patient management strategies.

Main Results:

• HU effectively treats myeloproliferative disorders like polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
• It plays a crucial role in combination therapies for malignant melanoma, head and neck cancers, and brain tumors.
• HU offers the benefit of ambulatory administration with minimal clinical toxicity.
• Common limitations include gastrointestinal disturbances and bone marrow depression.

Conclusions:

• Hydroxyurea (HU) is a valuable chemotherapeutic agent with a specific mechanism targeting DNA synthesis.
• Its efficacy in hematological malignancies and various cancers, often in combination therapy, is well-established.
• While generally well-tolerated, potential toxicities require careful patient monitoring and management.